Alzamend Neuro, Inc.
Develops treatments for neurodegenerative diseases and psychiatric disorders.
ALZN | US
Overview
Corporate Details
- ISIN(s):
- US02262M3088
- LEI:
- Country:
- United States of America
- Address:
- 480 PEACHTREE ROAD NE, SECOND FLOOR, 30326 ATLANTA
- Website:
- https://alzamend.com/
- Sector:
- Manufacturing
Description
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Its primary targets include Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). The company's pipeline consists of two therapeutic drug candidates licensed from the University of South Florida Research Foundation. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate. ALZN002 is a patented cell-based therapeutic vaccine designed to restore the patient's immunological system's ability to combat Alzheimer's disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Alzamend Neuro, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alzamend Neuro, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alzamend Neuro, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
